Recorded device evidence

KARL STORZ ICG Imaging System (K162882): indications, design and recorded evidence

The acquired K162882 file contains product-specific indications and users, design and operating principle, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-08. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 18 selected decisions under primary code OWN. 18 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K162882 ↗ · this pageKARL STORZ ICG Imaging System2016-10-14 → 2017-01-26104Traditional
K262547 ↗KARL STORZ TIPCAM1 Rubina2026-07-23 → 2026-09-2160Traditional
K254180 ↗PerfusiX-Imaging2025-12-23 → 2026-07-24213Traditional
K242163 ↗SmartSurgN Visualization System2024-07-24 → 2026-04-20635Traditional
K254242 ↗KARL STORZ ICG Imaging System with RUBINA® Lens2025-12-29 → 2026-02-2659Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K162882 · PDF page 5 ↗ Source 2

The KARL STORZ ICG  Imaging System is intended to provide real-
                          time visible and near-infrared fluorescence imaging.

Indications For           The KARL STORZ ICG  Imaging System is intended to provide  real-
Use:                      time visible (VIS) and near-infrared (NIR) fluorescence imaging.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K162882 · PDF page 4 ↗ Source 3

The KARL STORZ ICG  Imaging System is used to provide real-time
                         high definition (HD) endoscopic or telescope images of visible
                         (VIS) and near-infrare d  (NIR) indocyanine green (ICG) dye
                         fluorescence during mi nimally invasive or open surgery.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K162882 · PDF page 7 ↗ Source 4

for its functions and performance, including verification that the
                              spectral characteristics of the ICG system illumi nation light
                              source, light transmission system, and telescope enable a selective
                              visualization of the ICG  fluorescence signal as detected by the
                              camera system.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK162882 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryKARL STORZ ICG Imaging System [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantKARL STORZ Endoscopy-America, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeOWN [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2017-01-26 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2016-10-14 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[141743] · record 5a3711209797bba9e151a93e75206b402a6719d687e11c23e41c47f260f25e8e
  • [5] Complete results array / fda-decision-context:K162882 · record whole dataset partition

FDA 510(k) summary — K162882 ↗

Fri, 03 Feb 2017 21:05:34 GMT · retrieved 2026-10-08

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot be3129412e9723d8fc853078fd0bbeb803228de6c43dd12e7de78a9b8c2c85ab

  • [2] PDF page 5 · record de6c71e21d83119e50de574f1817c1c2d12f51c01a25a191d673608776068972
  • [3] PDF page 4 · record 138bfb564db25f672ca97e9def2b7dafeddb9e0774cd70d6fbc65914958b7c74
  • [4] PDF page 7 · record 4ead4f70e8ca0a65af8aaa3d5763dc5f828db97f7fc9e7656fc9b272dc0b5083

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services